BRIEF published on 01/12/2026 at 07:35, 8 months ago Renewal of the marketing authorization for Sibnayal® in the European Union Kidney Disease EMA Advicenna AMM Sibnayal®
BRIEF published on 01/12/2026 at 07:35, 8 months ago Renouvellement de l'AMM de Sibnayal® dans l'Union Européenne Advicenne Maladies Rénales EMA AMM Sibnayal®
PRESS RELEASE published on 01/12/2026 at 07:30, 8 months ago Informations privilégiées / Autres communiqués Advicenne annonce le succès du renouvellement de l’AMM de Sibnayal® dans l’Union Européenne. L'EMA a validé l'autorisation de mise sur le marché, renforçant le développement commercial de Sibnayal® Renouvellement Union Européenne Advicenne AMM Sibnayal
BRIEF published on 11/04/2025 at 11:35, 10 months 8 days ago Advicenne submits Sibnayal® to the US FDA FDA Advicenna Sibnayal® Renal Tubular Acidosis Registration Filing
BRIEF published on 11/04/2025 at 11:35, 10 months 8 days ago Advicenne soumet Sibnayal® à la FDA américaine FDA Advicenne Sibnayal® Acidose Tubulaire Rénale Dépôt D'enregistrement
PRESS RELEASE published on 11/04/2025 at 11:30, 10 months 8 days ago Inside Information / Other news releases Advicenne submits registration application for Sibnayal® in dRTA treatment to US FDA, designated orphan drug. Evaluation process expected to take 12 months Advicenne Sibnayal® US FDA DRTA Treatment Registration Application
PRESS RELEASE published on 11/04/2025 at 11:30, 10 months 8 days ago Informations privilégiées / Autres communiqués Advicenne dépose le dossier d'enregistrement de Sibnayal® auprès de la FDA américaine pour le traitement de l'ATRd. Webconférence le 5 novembre 2025. Informations sur ADV7103 et le développement clinique FDA Advicenne Webconférence ATRd Sibnayal
BRIEF published on 09/19/2025 at 18:05, 11 months 22 days ago Advicenne: Half-year results in 2025 and outlook Financial Results Outlook Turnover United States Sibnayal®
BRIEF published on 09/19/2025 at 18:05, 11 months 22 days ago Advicenne : Résultats semestriels en 2025 et perspectives Chiffre D'affaires Résultats Financiers Perspectives États-Unis Sibnayal®
PRESS RELEASE published on 09/19/2025 at 18:00, 11 months 22 days ago Informations privilégiées / Communiqué sur comptes, résultats Advicenne présente ses résultats financiers semestriels au 30 juin 2025 et fait le point sur ses activités. Augmentation du chiffre d'affaires et perspectives favorables avec Sibnayal® Résultats Financiers Croissance Perspectives Advicenne Sibnayal®
Published on 09/12/2026 at 02:35, 11 hours 40 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 15 hours 15 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 16 hours 10 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 16 hours 50 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 21 hours 15 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 6 hours 45 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 16 hours ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 16 hours 5 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 18 hours 31 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 20 hours ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 7 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 7 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 18 hours ago Availability of the 2026 Interim Financial Report
